research PMON281 PERSISTENT VIRILIZATION AND VASOMOTOR SYMPTOMS IN A TRANSMAN 5-YEARS POST TESTOSTERONE WITHDRAWAL
A transman experienced lasting virilization symptoms after stopping testosterone, which were resolved with estradiol treatment.
Search
forProducts matching "prostate size"
Tracking 2 products like 165 Urimax D (Tamsulosin HCl/Dutasteride 0.4mg/0.5mg) and 184 DUTASTERIDE / TAMSULOZIN 0.5 MG from by companies like Inhouse Pharmacy and OnlinePharmacy-BG. View all 2 products »
Sort by
Research
660-690 / 1000+ results 
research Hormonal Treatment for Skin Androgen-Related Disorders
Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.
research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Finasteride effectively treats BPH but may increase sexual dysfunction risk.
research Exogenous Testosterone (T) Alone or with Finasteride Increases Physical Performance, Grip Strength, and Lean Body Mass in Older Men with Low Serum T
Testosterone therapy improves physical function, strength, and body composition in older men with low testosterone levels.
research Effects of Finasteride (MK-906), a 5α-Reductase Inhibitor, on Circulating Androgens in Male Volunteers*
Finasteride safely lowers DHT levels without affecting testosterone.
research Finasteride: A slow-binding 5.alpha.-reductase inhibitor
Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.
research C19and C215β/5αMetabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency*
Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.
research Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia
Finasteride-loaded nanoparticles may help treat alopecia.
research The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride
Lovastatin doesn't improve lower urinary tract symptoms treatment.
research Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins
Cyclodextrins improve finasteride's solubility and bioavailability for hair loss treatment.
research Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population
Metabolic syndrome linked to urinary symptoms; hair loss not significant.
research Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.
research Finasteride, A Steroid 5α-Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine
Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.
research 5α-Metabolism in Finasteride-Treated Subjects and Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency
Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.
research Pharmacokinetic Interaction between Finasteride and Terazosin, but not Finasteride and Doxazosin
Finasteride interacts with terazosin, but not doxazosin; caution needed.
research SIMULTANEOUS DETERMINATION OF FINASTERIDE AND TAMSULOSIN IN COMBINED DOSAGE FORM BY USING RP-HPLC METHOD
Method accurately measures finasteride and tamsulosin in combined drug form.
research 5α-reductase inhibitors
5α-reductase inhibitors help treat disorders caused by DHT and have potential for future therapies.
research Chromatographic methods for determination of finasteride and tamsulosin hydrochloride and in presence of finasteride degradation product
Two methods can measure finasteride and tamsulosin hydrochloride; HPLC is more advantageous, while TLC offers better separation.
research A retrospective study of clinical outcomes of α-blocker or finasteride monotherapy followed by combination therapy: determination of the period of combination therapy of α-blocker and finasteride
Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.
research UV SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF FINASTERIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM
The method measures finasteride accurately and cheaply using UV light.
research UV SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS DETERMINATION OF FINASTERIDE AND TAMSULOSIN IN COMBINED DOSAGE FORM
Researchers developed a quick and accurate method to measure finasteride and tamsulosin in tablets.
research Post-finasteride Syndrome: A Review of Current Literature
Post-finasteride Syndrome causes lasting negative effects, but more research is needed for treatment and risk evaluation.
research Finasteride
Finasteride helps hair growth.
research Picogram determination of finasteride in human plasma and semen by high-performance liquid chromatography with atmospheric-pressure chemical-ionization tandem mass spectrometry
Method detects finasteride in plasma and semen with high sensitivity and accuracy.
research Stem Cells and the Niche: A Dynamic Duo
Stem cell niches are crucial for regulating stem cell behavior and tissue health, and their decline can impact aging and cancer.
research Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors
Hair loss increases with age; alcohol raises risk, more female partners lowers it.
research Genetic prediction of male pattern baldness
Genetic factors can help predict male pattern baldness risk.
research External genitalia abnormalities in male rats exposed in utero to finasteride, a 5α-reductase inhibitor
Finasteride exposure in pregnancy causes genital abnormalities in male rats.
research Male-pattern baldness susceptibility locus at 20p11
Researchers found a new gene area linked to male-pattern baldness, which, along with another gene, significantly increases the risk of hair loss in men.
research Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31
A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.